The promise of immune-directed cellular therapies is great – so are the challenges of translating the science into clinical trials which could lead to approved therapeutics for diseases states like auto-immunity, infection and cancer. In pediatric medicine, these translational challenges are exacerbated by the “orphan” scale of incidence, limited pediatric-dedicated cGMP production facilities and the low financial returns which make industry-sponsored research less likely.

The Consortium for Pediatric Cellular Immunotherapy is working to address these challenges by pooling its expertise and sharing its learnings with the broader community. By working together, we believe we can accelerate innovation in the field and bring these life-saving treatments to children more quickly and efficiently.